Skip to main content

07-12-2021 | Rheumatology | News | Article

Subclinical synovitis precedes inflammatory arthritis in anti-CCP2+ at-risk people

Author: Laura Cowen

medwireNews: The majority of people with anti-cyclic citrullinated peptide (CCP)2 antibodies and musculoskeletal symptoms without clinical synovitis have a period of subclinical synovitis that precedes inflammatory arthritis, research shows.

This preclinical period may be predicted by the presence of anti-CCP3 antibodies, suggesting that identifying patients with musculoskeletal symptoms who are positive for both anti-CCP2 and anti-CCP3 but with no clinical synovitis “may represent the optimal ‘window of opportunity’ for intervention to prevent joint disease,” write Paul Emery (University of Leeds, UK) and co-authors in Rheumatology.

Emery and team reviewed ultrasound scans from 97 such individuals, defined as CCP2+ at-risk, who ultimately progressed to inflammatory arthritis.

Of these, 77.3% had ultrasound subclinical synovitis, which was first detected a median of 26.5 weeks before the development of inflammatory arthritis.

The wrist was the most common location for subclinical synovitis, with 60.0% of affected participants positive at this site, followed by metacarpophalangeal joints (40.0%), metatarsophalangeal joints (29.3%), proximal interphalangeal joints (22.7%), knees (8.0%), and elbows and ankles (1.3% each).

The researchers then reviewed longitudinal ultrasounds from 220 CCP2+ at-risk individuals who had no baseline ultrasound abnormalities and found that 31.4% subsequently developed ultrasound synovitis, at a median of 56.4 weeks from baseline after a median of two ultrasound scans. These patients had a median of two joints affected.

Multivariate analyses revealed that the presence of anti-CCP3 antibodies was the only variable significantly associated with the development of ultrasound synovitis, with an odds ratio of 4.75.

Indeed, 18.9% and 34.2% of individuals positive for both anti-CCP2 and anti-CCP3 antibodies developed subclinical synovitis at 1 and 2 years, respectively.

This was significantly higher than the corresponding rates of 6.4% and 10.1% observed among the people who were positive for anti-CCP2 but negative for anti-CCP3.

Of note, neither the presence of a high level of anti-CCP2 antibodies nor that of rheumatoid factor predicted the development of ultrasound subclinical synovitis.

Emery et al conclude that the majority of CCP2+ at-risk individuals who progress to inflammatory arthritis go through a stage of ultrasound subclinical joint inflammation that represents “a distinct and important stage of the RA [rheumatoid arthritis] ‘continuum’.”

They add: “Anti-CCP3 antibodies have a potential role in the identification of CCP2+ individuals who are about to develop clinical or subclinical RA-related joint inflammation (i.e., before the ‘second hit’ in RA pathogenesis occurs).”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Rheumatology 2021; doi:10.1093/rheumatology/keab862

See the research in context now

with trial summaries, expert opinion and congress coverage